Processa Pharmaceuticals ... (PCSA)

NASDAQ: PCSA · Real-Time Price · USD

0.25

-0.01 (-3.03%)

At close: May 01, 2025, 3:59 PM

0.23

-8.80%

Pre-market: May 02, 2025, 05:39 AM EDT

-3.03% (1D)

Bid	0.18
Market Cap	1.32M
Revenue (ttm)	n/a
Net Income (ttm)	-11.85M
EPS (ttm)	-3.87
PE Ratio (ttm)	-0.06
Forward PE	-0.29
Analyst	Buy

Ask	0.3
Volume	3,318,994
Avg. Volume (20D)	2,226,090
Open	0.24
Previous Close	0.26
Day's Range	0.23 - 0.25
52-Week Range	0.15 - 3.10
Beta	1.04

About PCSA

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selectiv...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 7, 2014

Employees 10

Stock Exchange NASDAQ

Ticker Symbol PCSA

Website https://www.processapharmaceuticals.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for PCSA stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 2300.00% from the latest price.

Stock Forecasts

Why Price Moved

3 months ago

-3.7%

Processa Pharmaceuticals shares are trading lower ... Unlock content with Pro Subscription

7 months ago

+0%

Processa Pharmaceuticals shares are trading higher after the company announced the dosing of its first patient for the Phase 2 trial of NGC-Cap.

News

9 months ago · investorplace.com

Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?

Processa Pharmaceuticals (NASDAQ: PCSA ) stock is rising higher on Tuesday after the company posted an update from the Food and Drug Administration (FDA). The FDA has cleared Processa Pharmaceuticals ...

1 year ago · investorplace.com

Why Is Processa Therapeutics (PCSA) Stock Up 90% Today?

Clinical-stage pharmaceutical company Processa Therapeutics (NASDAQ: PCSA ) — which specializes in the field of oncology — is skyrocketing on Thursday. PCSA stock is up about 90% as of this writing, a...

1 year ago · invezz.com

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Processa Pharmaceuticals Inc (NASDAQ: PCSA) says it has completed a safety evaluation of its cancer treatment. Its shares rallied well over 150% on Thursday.

1 year ago · pennystocks.com

Best Penny Stocks Under $1? 4 To Watch This Week

What are the best penny stocks under $1? If you saw this headline, that's probably a question you have heading into the second half of the week.

2 years ago · zacks.com

Heatwurx Inc. (PCSA) Upgraded to Buy: Here's What You Should Know

Heatwurx Inc. (PCSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 years ago · seekingalpha.com

Processa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call Transcript

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Jim Stanker - CFO David Young - President & CEO Conference Call Particip...

2 years ago · seekingalpha.com

Processa Pharmaceuticals, Inc. (PCSA) CEO David Young on Q2 2022 Results - Earnings Call Transcript

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants James Stanker - Chief Financial Officer David Young - President and Chief...

2 years ago · seekingalpha.com

Processa Pharmaceuticals' (PCSA) CEO David Young on Q1 2022 Results - Earnings Call Transcript

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jim Stanker – Chief Financial Officer David Young – Chief Executive Officer ...